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Abstract
The angiogenic potential of a cell requires dynamic reorganization of the cytoskeletal architecture that involves the
interaction of urokinase-type plasminogen activator receptor (uPAR) with the extracellular matrix. This study focuses
on the effect of uPAR deficiency (uPAR
-/-) on angiogenic function and associated cytoskeletal organization. Utilizing
murine endothelial cells, it was observed that adhesion, migration, proliferation, and capillary tube formation were
altered in uPAR
-/- cells compared to wild-type (WT) cells. On a vitronectin (Vn) matrix, uPAR
-/- cells acquired a “fried
egg” morphology characterized by circular actin organization and lack of lamellipodia formation. The up-regulation
of b1 integrin, FAK(P-Tyr925), and paxillin (P-Tyr118), and decreased Rac1 activation, suggested increased focal
adhesions, but delayed focal adhesion turnover in uPAR
-/- cells. This accounted for the enhanced adhesion, but
attenuated migration, on Vn. VEGF-enriched Matrigel implants from uPAR
-/- mice demonstrated a lack of mature
vessel formation compared to WT mice. Collectively, these results indicate that a uPAR deficiency leads to
decreased angiogenic functions of endothelial cells.
Introduction
Neovascularization, by way of angiogenesis, involves a
series of tightly regulated cellular processes. As a patho-
logical event that is required for growth and survival of
tumor cells, angiogenic signals consist of growth factors
released in the microenvironment by the hypoxic tumor.
These growth factors activate quiescent endothelial cells
(ECs), leading to disruption of cell-extracellular matrix
(ECM) contacts. Subsequently, the ECs undergo con-
certed changes in morphology and cytoskeletal config-
uration [1]. These processes enable growth factor-
induced migration [2], followed by adhesion [3], prolif-
eration, and formation of a new vascular lumen, even-
tually leading to development of a blood vessel [4]. The
initial disruption of the EC-ECM contact requires degra-
dation of the ECM, which is facilitated by a variety of
proteases. The urokinase-plasminogen activator receptor
(uPAR) binds to urokinase-plasminogen activator (uPA)
[5,6], which in-turn localizes the activation of plasmino-
gen (Pg) to the extracellular protease, plasmin (Pm) [7].
Pm then catalyzes degradation of the ECM and also
activates other proteases, which together facilitate EC
migration. Additionally, uPAR, by lateral interactions
with its transmembrane partners, e.g., integrins [8] and
low-density lipoprotein receptor-related protein (LRP),
functionally orchestrates bidirectional signaling events
that affect migration, adhesion, and proliferation [9].
The ability of uPAR to interact with cytoskeletal compo-
nents, such as vinculin, Rac, and focal adhesion kinase
(FAK), at sites of EC-ECM contacts, strongly implicates
its role in cytoskeletal rearrangement [10-12].
uPAR can directly interact with vitronectin (Vn), and
this interaction may be enhanced by uPA, thus promot-
ing cellular events leading to angiogenesis [8]. Several
studies have shown that increased expression of uPAR,
which is upregulated in different cancers [13-18], results
in increased adhesion to Vn. Hence, down-regulating
uPAR expression would potentially not only disrupt
cell-associated uPA, but also binding to matrix proteins,
thereby suppressing tumorg r o w t ha n di n v a s i o n .A
uPAR deficiency would also affect reciprocal molecular
binding of integrins to ECM proteins, modulating sig-
naling events and cytoskeleton morphology. Thus, loss
of uPAR function disrupts the integrated processes of
pericellular proteolysis, cell adhesion and migration, and
downstream signaling events. This is confirmed in
* Correspondence: vploplis@nd.edu
1W. M. Keck Center for Transgene Research, University of Notre Dame, 230
Raclin-Carmichael Hall, Notre Dame, Indiana 46556, USA
Full list of author information is available at the end of the article
Balsara et al. Vascular Cell 2011, 3:10
http://www.vascularcell.com/content/3/1/10 VASCULAR CELL
© 2011 Balsara et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.studies that showed that attenuated uPAR expression in
tumor cell lines inhibited tumor cell migration and inva-
siveness, and led to inactivation of ERK1/2 signaling and
rearrangement of the cytoskeleton architecture [18,19].
Further, silencing uPAR expression in CFPAC-1 and
PANC-1 pancreatic ductal adenocarcinoma cell lines
significantly inhibited cell proliferation and migration
with an increase in apoptosis [19]. On the other hand
overexpression of uPAR in HEK293 cells increased
adhesion to Vn, with marked display of protrusions and
lamellipodia, compared to mock-transfected cells
[20,21]. Thus, it appears that direct interaction of uPAR
with Vn leads to matrix adhesion, followed by lateral
engagement with integrins, which activates downstream
events such as changes in cell morphology, migration,
and signal transduction [20].
It is apparent that changes in the physiological levels
of uPAR have biological consequences in this regard.
Increased expression of uPAR enhanced adhesive and
migratory properties of cells accompanied by increased
ERK1/2 activation [20], whereas diminished uPAR levels
in cancer cells proved to be detrimental for tumor
growth and invasiveness [22]. However, implications of
diminished uPAR expression, and its effect on the
angiogenic functions of cells, are not well documented.
Since uPAR plays an important role in angiogenesis, as
well as coordinating various cellular responses, such as
interaction with matrices, signaling, and cell morphol-
ogy, a total deficiency of uPAR on these processes was
comprehensively evaluated utilizing physiologically rele-
vant primary ECs isolated from aortas of wild-type
(WT) and uPAR
-/- mice.
Materials and methods
Materials
Complete cell culture medium for ECs consisted of
RPMI 1640 (Mediatech, Herndon, VA), 20% fetal bovine
serum (Invitrogen, Carlsbad, CA), 1% antibiotic/antimy-
cotic mixture (1000 units of penicillin, 0.1 mg of strep-
tomycin, 0.25 μg amphotericin B) (Sigma, Saint Louis,
MO), 50 μg/ml endothelial growth factor supplement
(BD Biosciences, San Jose, CA), 2 mM glutamine (Med-
iatech), 0.1 mM amino acids (Invitrogen), and 1 μl/ml
b-mercaptoethanol (Invitrogen). Primary antibodies uti-
lized were rabbit anti-human-total FAK, rabbit anti-
human-total paxillin, rabbit anti-human-phospho-FAK,
rabbit anti-human RhoA, rabbit anti-human Rac1/2/3
(L129), and rabbit anti-human STAT1 were from Cell
Signaling Technology (Danvers, MA). Armenian hamster
anti-mouse integrin b1 monoclonal antibody, goat anti-
human integrin b3, and mouse anti-porcine tubulin
monoclonal antibody were from Santa Cruz Biotechnol-
ogy (Santa Cruz, CA). Rabbit anti-human paxillin(P-
Tyr118) polyclonal antibody conjugated to Alexa Fluor
488 was from Invitrogen. For actin visualization, phalloi-
din conjugated to either Alexa Fluor 488 or 594 (Invi-
trogen) was utilized. Where required the secondary
antibodies were HRP-conjugated goat anti-rabbit IgG
(Cell Signaling Technology), goat anti-mouse IgM, and
goat anti-armenian hamster (Santa Cruz Biotechnology).
Mouse anti-human uPA and mouse anti-human vinculin
antibodies were from Abcam (Cambridge, MA) and rab-
bit anti-rat PAI-1 from American Diagnostica (Stamford,
CT). Vitronectin was from Sigma and fibronectin and
rat-tail type I collagen was from BD Biosciences. Rabbit
anti-human microtubulin polyclonal antibody was kindly
provided by Dr. Holly Goodson (University of Notre
Dame, IN, USA).
Mice
Mice with a homozygous deficiency of urokinase-type
plasminogen activator receptor (uPAR
-/-)h a v ep r e -
viously been described [23]. The uPAR
-/- mice utilized
in this study lacked the second and fifth exon of the
uPAR gene resulting in complete inactivation of the
gene product. Wild type mice (C57BL/6J) were obtained
from the Jackson Laboratory (Bar Harbor, ME) and
were used as controls. Male mice between 8 and 12 wks
of age were utilized for this study. Mice were anesthe-
tized intraperitoneally with a rodent mixture (0.015 mg
of xylazine, 0.075 mg of ketamine, and 0.0025 mg of
aceprozamine/g body weight). Experimental protocols
were approved by the Institutional Animal Care and Use
Committee of the University of Notre Dame.
Methods
Isolation of EC
Aortic ECs were isolated as previously described [24].
The aortas were cut into 10 pieces and then opened
longitudinally. Each segment was placed lumen side
down on a collagen gel and incubated for 36 hr. Fresh
media was added and cells were allowed to become con-
fluent (7-10 days). Automated EC purification was based
on selecting a subset of cells that are positive for CD105
and/or CD106 expression utilizing a RoboSep (Stem
Cell Research, Vancouver, Canada). All cell culture
experiments were performed at 37°C in a humidified
6.5% CO2 incubator.
Adhesion assay
Twenty four-well plates were coated with Vn (1.5 μg/
ml) or Fn (10 μg/ml) at 4°C overnight. Plates coated
with collagen (1 mg/ml) were incubated for 1 hr at RT.
The wells were aspirated and the plates were treated
with 1% BSA for 1 hr at 37°C to prevent non-specific
binding. Wells coated with 40 μg/ml of BSA served as
controls for the adhesion assay. ECs were placed in
serum-free medium for 1 hr to induce quiescence. EC
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4 cells/ml in RPMI/0.2%
BSA, and 1 ml was added to each well. After the desig-
nated incubation time, the cells were placed on a Jitter-
bug™ model 130000 (Boekel Scientific, Feasterville, PA)
for 2 minutes and then washed with PBS to remove
non-adherent cells. The adherent cells were fixed with
cytofix, stained with Hematoxylin (Vector Laboratories),
viewed with a Nikon Eclipse TE200 microscope, and
imaged using the SPOT camera and the SPOT advanced
version 4.0.9 software (Diagnostic Instruments, Inc.).
Cell counts were determined in triplicate using a 40×
objective (three fields/well).
Migration assay
Migration assays were performed on 6-well Vn- (1.5 ug/
ml) or collagen- (1 mg/ml) coated plates. 6 × 10
5 quiescent
cells in RPMI were added to each well and allowed to
adhere overnight. The next day, a scratch was induced
with a 200 μl tip, the cells washed with PBS and then incu-
bated in RPMI containing 10 ng/ml of VEGF as a che-
moattractant. Images were captured immediately after
scratch induction and 24 hr after scratch induction with a
Nikon Eclipse TE200 microscope utilizing a 10× objective,
the SPOT camera, and SPOT advanced version 4.0.9 soft-
ware. The number of cells that had migrated to the
scratched area was counted. For uPA/PAI-1 colocalization
staining, WT and uPAR
-/- ECs were seeded on Vn-coated
2-well multi-chambered slides (Grace Biolabs, Bend, OR)
and allowed to reach confluency. A scratch was then
induced, and migration allowed to occur for 24 hr. The
cells were fixed with 4% paraformaldehyde and stained for
PAI-1 and uPA (as described for immunofluorescence).
Proliferation assay
Cells were resuspended at 1 × 10
5 cells/ml in complete
medium. An aliquot of 1 ml was added to Vn-coated or
collagen-coated 6-well plates. The cells were then incu-
bated for 24 hr. The medium was then removed, fresh
complete medium without EC growth factor supplement
was added, and the plates incubated at 37°C. Total cell
counts were performed at 24 and 48 hr. For this, the
medium was removed, and the wells were rinsed with
PBS. Adherent cells were detached either with collage-
nase (Invitrogen) or trypsin-EDTA, stained with trypan
blue (Sigma), and counted using a hemocytometer.
Western blot
WT and uPAR
-/- ECs that were allowed to adhere on
Vn for 4 hr were detached by trypsin-EDTA for 5 min
and then lysed in cell lysis buffer (Cell Signaling Tech-
nology) for 10 min on ice. The cell lysates were centri-
fuged and total protein concentration of the supernatant
was determined by the BCA assay (Pierce, Rockford, IL).
Supernatants were fractionated on 10% SDS-PAGE gels,
blotted on polyvinylidene difluoride membranes (Osmo-
nics Inc.), and immunoassayed according to the manu-
facturer’s protocol. Densitometric analyses of Western
autoradiograms were performed using the Scion pro-
gram downloaded from NIH (available on the World
Wide Web at http://www.scioncorp.com).
Immunoprecipitation
For detection of integrins b1, b3, and FAK(P-Tyr925),
immunoprecipitation of 100 μgo fW Ta n du P A R
-/- cell
lysates from ECs adherent on Vn for 4 hr was per-
formed using an antigen specific antibody and incubated
overnight at 4°C. Lysates were then gently rocked for 3
hr with protein A beads (Pierce) at 4°C. The mixture
was centrifuged and washed 5× in lysis buffer, sus-
pended in SDS-PAGE loading buffer, and resolved in a
10% polyacrylamide gel. Western blots were then
performed.
Immunofluorescence microscopy
WT and uPAR
-/- cells plated on Vn or collagen-coated
multi-chambered wells (Grace Biolabs) were fixed with
either 4% paraformaldehyde for 10 min. or ice-cold
methanol for 5 min. Cells not fixed in methanol were
permeabilized with 0.1% Triton X-100, and blocked with
10% normal serum (Jackson Immunoresearch, West
Grove, PA) followed by treatment with Image-iT FX sig-
nal enhancer (Invitrogen). Cells were incubated with pri-
mary antibody, washed, and then incubated with the
appropriate Alexa Fluor secondary antibody (488 or
594) (Molecular Probes). Cells stained for actin or paxil-
lin(P-Tyr118) were permeabilized with 0.1% Triton X-
100/PBS at RT for 5 min, washed 3×, and incubated
with Image-iT FX for 30 min. The conjugated primary
antibody diluted (1:500 for phalloidin, 1:50 for phospho-
pax) in 1% BSA/PBS was then added and incubated
overnight at 4°; C. After labeling, the slides were rinsed
and cover slipped. Coverslips were mounted with Pro-
Long Gold antifade reagent containing DAPI (Invitro-
gen). Images were captured using a Nikon Eclipse
TE2000-U with the BD CARV spinning disk confocal
unit and images were acquired using Metamorph 7.0
software.
Rac activity assay
Rac1 activity was measured utilizing the Rac1 activation
assay kit according to the manufacturer’sp r o t o c o l
(Thermo Scientific, Rockford, IL). WT and uPAR
-/- ECs
adherent on Vn for 4 hr were harvested in lysis/binding/
wash buffer containing 1× protease inhibitor cocktail
(Thermo Scientific). Briefly, one Immobilized Glu-
tathione SwellGell Disc was placed in a spin tube for
each genotype and to that was added 20 μgo fG S T -
human Pak1-PBD. Immediately 800 μg of cell lysates
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at 4°C with gentle rocking for 1 hr. The resin was
washed 3× with the lysis/binding/wash buffer and the
Rac activation pull-down reaction was retrieved by add-
ing 50 μl of 2× SDS Sample buffer containing 1 part b-
mercaptoethanol and centrifuging at 7,200 × g for 2
min. The samples were fractionated by SDS-PAGE
using a 12% gel and subjected to immunoblot analysis
utilizing anti-Rac 1 mouse monoclonal antibody. The
secondary antibody was goat anti-mouse HRP conju-
gated IgG and detection was by chemiluminescent. The
presence of active Rac was determined by the appear-
ance of the 22 kDa Rac-GTP band.
Matrigel assay
An in vivo angiogenesis assay utilizing Matrigel Base-
ment Membrane Matrix (BD Biosciences) was per-
formed. Matrigel solution was supplemented with VEGF
(10 ng/ml) and 0.4 ml was administered to WT and
uPAR
-/- mice (3 mice/genotype) by dorsal subcutaneous
injection. All mice utilized in this experiment were 8-10
wk old males. The implants were removed at day 14
and fixed in PLP (Paraformaldehyde/Lysine/Periodate).
The excised plugs were stained for smooth muscle a-
actin by first permeabilizing with 0.05% Triton X-100,
followed by blocking with normal goat serum for 30
min with agitation. The gels were incubated with a
mouse monoclonal antibody against human smooth
muscle a-actin (Sigma) at 4°; C/overnight, washed,
stained with Alexa Fluor 488 (Invitrogen) and then
visualized utilizing an Olympus FV 1000 Laser Scanning
Confocal microscope with ASW software (NDIIF, Uni-
versity of Notre Dame, USA).
In vitro sprout formation assay
The ability of WT and uPAR
-/- ECs to undergo tubulo-
genesis, in vitro, was determined as previously described
[25]. Microcarrier cytodex (Sigma) beads were mixed
with 5 × 10
6 cells and seeded in a fibrinogen (ERL,
South Bend, IN) gel in a 2-well multi-chambered slide.
Polymerization of fibrin was initiated by adding 0.48 U/
ml thrombin (ERL) for 5 min at RT. To each well 1 ml
of complete RPMI was added and incubated for 1 h at
37°; C, after which the medium was aspirated and 1 ml
of complete RPMI in the presence or absence of 10 ng/
ml VEGF was added. The mixture was allowed to incu-
b a t ef o re i t h e r2 4o r9 6h ra t3 7 ° ;C / 6 . 5 %C O 2,a f t e r
which the gel was fixed with 1% paraformaldehdye/PBS
for 3 h at 4°; C. The cells were permeabilized with 0.3%
Triton X-100 for 5 min at room temperature and then
treated with Image-iT Fx Signal Enhancer (Invitrogen)
for 30 min. The cells were washed with PBS 3× and
blocked with a serum-free protein block (DAKO, Den-
mark) for 5 min. The cells were then incubated
overnight at 4°; C with phalloidin Alexa Fluor 594 (Invi-
trogen) to stain for actin. The next day the cells were
washed 3× with PBS and the gels were mounted with
DAPI containing ProLong Antifade reagent (Invitrogen).
Quantification of vessels in vitro
High resolution images of the beads (up to 10 beads/
well of each genotype/treatment) were acquired using a
Nikon TE 2000 S fluorescence microscope. The objec-
tive used was 100× (Nikon). The images were taken as a
z series stack, which allowed the inclusion of all sprouts.
The software interface NIS Nikon Elements was used to
capture the images as well as to quantify the number of
cells adherent per bead (performed by counting the
nuclei on a bead), sprouts per bead, and the sprout
length. After a 96 h incubation, images were acquired
using a 20× ELWD objective. All experiments were
repeated three times.
Statistical analysis
All experiments were performed at least three times.
The data are represented as the mean ± SEM and p
values of ≤ 0.05 obtained using Student’s t test were
considered to be statistically significant.
Results
A total uPAR deficiency perturbs adhesion, migration,
and proliferation of ECs
The ability of ECs to adhere to the ECM and reorganize
their cell morphology is a critical step in angiogenesis
[26]. uPAR has been implicated in pathological angio-
genesis [9] and, due to the ability of the receptor to
functionally interact with ECM [27], integrins [28,29],
and G-protein-coupled receptors [30], uPAR can facili-
tate different angiogenic events. WT and uPAR
-/- ECs
were utilized to study the processes associated with
angiogenesis, i.e., adhesion, migration, and proliferation.
It was observed that uPAR
-/- ECs adhered more strongly
on Vn and collagen compared to WT cells (Figure 1A,
B). uPAR
-/- ECs displayed markedly increased adhesion
on Vn, which peaked at 4 hr, but was statistically signifi-
cant even after 24 hr (Figure 1A). However, adhesion of
uPAR
-/- ECs to fibronectin was unaffected (Figure 1C).
Since cell migration and proliferation are coupled to
adhesive properties of cells on the ECM, migration and
proliferation assays on Vn and collagen were performed. A
scratch assay was employed to assess the cellular motility
of ECs from both genotypes in the presence of Vascular
Endothelial Cell Growth Factor (VEGF), which is a major
facilitator of both physiological and pathological angiogen-
esis. Cell migration of uPAR
-/- ECs was diminished 60%
compared to WT cells when plated on Vn (Figure 2A).
However, migratory function of the uPAR
-/- ECs was not
affected on collagen. ECM proteolysis is controlled by the
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forms a 1:1 complex with uPA bound to uPAR, and cata-
lyzes the vesicular internalization of the uPA/PAI-1 com-
plex. This results in eventual degradation of both uPA and
PAI-1 [31]. Primary ECs express both uPA and PAI-1
[24], and since migration of uPAR
-/- c e l l si si m p a i r e do n
Vn, co-localization of uPA and PAI-1 by immunofluores-
cence on cells migrating in the presence of VEGF was per-
formed. In migrating WT cells, uPA and PAI-1 co-
localization was observed along the focal adhesions at the
advancing front of the cell (indicated by arrows) (Figure
2B). Co-localization of uPA/PAI-1 in the uPAR
-/- ECs was
observed abundantly within the cytoplasm (indicated by
arrows), with very little staining at focal adhesion points
(Figure 2C). ERK1/2 activation levels were not affected in
uPAR
-/- ECs compared to WT cells (data not shown) indi-
cating that changes in angiogenic function in these cells
are regulated by other signaling pathways.
The proliferative ability of uPAR
-/- ECs plated on Vn
(Figure 3A) was decreased compared to WT cells, but
n o tw h e np l a t e do nc o l l a g e n( F i g u r e3 B )a t2 4a n d4 8
hr. On Vn-coated plates, WT cell counts increased by
~3-fold from its initial plating density of 1 × 10
5 cells at
24 hr compared to uPAR
-/- ECs. At 48 hr the uPAR
-/-
cell counts have marginally increased compared to WT
cells on Vn-coated plates. The slight decrease in WT
cell counts at 48 hr when Vn is utilized as the matrix
could be attributed to a functional plasminogen activa-
tion system. Since the proliferation is a long-term assay,
it is possible that proteolysis of Vn could lead to cell
detachment. Therefore, while adhesion of uPAR
-/- cells
on Vn and collagen was increased, the migratory and
proliferative properties of the cells were only affected
when the cells were plated on Vn, and not on collagen.
Altered morphology of uPAR
-/- ECs is Vn-dependent
Our data demonstrated that uPAR
-/- cells had stronger
adhesive properties with concomitant decreased
migratory and proliferative abilities when plated on
Vn compared to WT cells. Since cell morphology on
the ECM is a critical parameter for determining cell
growth and apoptosis, the actin organization of
uPAR
-/- a n dW TE C sw a sa n a l y z e dw h e nc u l t u r e do n
both Vn and collagen. Immunofluorescence studies
revealed that the uPAR
-/- ECs showed typical “fried
egg” morphology with a lack of actin polarization and
lamellipodia formation when plated on Vn compared
to WT cells (Figure 4A,B). WT cells showed the
expected elongated cell shape with polarized actin and
several lamellipodia extensions (Figure 4A,C). The
actin architecture in uPAR
-/- ECs was observed as a
circular network of filaments around the nucleus with
Figure 1 An uPAR deficiency alters cell adhesion to Vn and collagen:( A) uPAR deficiency promotes EC adhesion to Vn as observed by
enhanced adhesion of uPAR
-/- ECs compared to WT cells. WT and uPAR
-/- cells on BSA serve as a control for this assay. (B) Enhanced adhesion
of uPAR
-/- ECs on collagen at 4 hr. (C) Adhesion of uPAR
-/- ECs is similar to WT cells when plated on fibronectin. BSA served as a negative
control matrix. The cell counts represent the mean ± SEM of three independent assays each performed in triplicate (40× field). Significance levels
(*) indicates p value of < 0.05 between WT and uPAR
-/- ECs.
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plasma membrane (Figure 4B,D). uPAR
-/- cells grown
on collagen did not exhibit the “fried egg” morphology
and were morphologically similar to WT cells (data
not shown).
Microtubules functionally interact with the actin cytos-
keleton and together they organize the cytoskeleton archi-
tecture, thus facilitating cell migration [32-34]. To
determine whether lack of uPAR has an influence on
microtubule configuration, WT and uPAR
-/- ECs adherent
Figure 2 Endothelial cell migration on Vn and uPA/PAI-1 co-localization are affected by a uPAR
-/- deficiency:( A)A b s e n c eo fu P A R
expression decreased EC migration on Vn but not on collagen. Quiescent WT and uPAR
-/- ECs were plated to confluency on Vn- and collagen-
coated 6-well dishes and a scratch induced. Migration was induced by the presence of VEGF (10 ng/ml) and images of the scratch area were
acquired immediately after the scratch and after 24 hr of incubation at 37°; C/6.5% CO2. The number of cells that had migrated in the scratch
area was counted and graphed as percent of migrated WT cells. The graph represents the mean ± SEM of three independent assays each
performed in triplicate. Significance levels (*) indicates p value of < 0.05 between WT and uPAR
-/- ECs. (B) uPA/PAI-1 co-localization is
cytoplasmic in migratory uPAR
-/- ECs. Fixed cells were stained with antibodies against uPA (green, Alexa Fluor 488) and PAI-1 (red, Alexa Fluor
647). Co-localization of uPA/PAI-1 in WT cells was observed along the focal adhesions or cell membrane (arrows). (C) In the uPAR
-/- ECs uPA/PAI-
1 co-localization was observed as extensive blobs within the cytoplasm (arrows).
Figure 3 uPAR
-/- ECs exhibited altered proliferation on Vn:( A) WT and uPAR
-/- ECs were seeded on Vn-coated plates at a density of 1 × 10
5
cells/ml as described. Graph represents total cell counts measured at 24 and 48 hr (mean ± SEM) of three independent assays. At both time
points proliferation of uPAR
-/- ECs was significantly diminished compared to WT cells. p values between WT and uPAR
-/- ECs at both time points
were <0.05. (B) Proliferation of WT and uPAR
-/- ECs is similar on collagen-coated plates at 24 and 48 hr.
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for polymerized a-tubulin (kindly provided by Dr. Holly
Goodson). When WT and uPAR
-/- ECs were plated on
Vn, no differences in the morphology of microtubule orga-
nization were noted. Both genotypes exhibited a promi-
nent microtubule-organizing center (MTOC) with the
microtubules growing radially towards the cell periphery
(Additional File 1, Figure S1A , B ) .H o w e v e r ,o nc o l l a g e n
the microtubulin organizations in uPAR
-/- ECs appeared
to be arranged in parallel bundles, as opposed to the radial
petal-like configuration observed in WT cells (Additional
File 1, Figure S1C,D). This may be a function of microtu-
bules in uPAR
-/- cells having a greater number of contact
points with the cell cortex, as the petal motif in the WT
cells arise from the convergence of microtubules to a few
specific points on the membrane.
Effect of uPAR-deficiency on cytoskeletal-associated
signaling in ECs
Since adhesion of ECs to the ECM requires formation
of focal adhesions that form cell-matrix junctions that
aid in anchoring cytoskeletal proteins to the matrix
[35], focal adhesion kinase (FAK) and paxillin, which
are key components of focal adhesions that become
phosphorylated when cells adhere to the ECM [36],
were examined. The cellular distributions of FAK(P-
Tyr925) and Pax(P-Tyr118) were evaluated in WT and
uPAR
-/- ECs. After 4 hr adhesion on Vn, FAK(P-
Tyr925) was observed as small punctate signals, mainly
in the cytoplasmic region of the WT cells, with very
little staining observed on the membrane edge (Figure
5A). However, in uPAR
-/- ECs FAK(P-Tyr925) was
prominently localized in the central adhesion regions
with some localization on the membrane edge (Figure
5B). Additionally, elevated levels of FAK(P-Tyr925)
were observed in uPAR
-/- ECs by immunoblotting (Fig-
ure 5E) and densitometric analyses (Figure 5F). Phos-
phorylation of FAK at Tyr925 as well as at other sites
(Tyr407, 576, 577, and 861) is Src-dependent [37-40]
and is essential for regulating F-actin assembly and
maintaining cell adhesion dynamics [41]. Phosphoryla-
tion of endogenous FAK at Tyr925 is known to
Figure 4 Actin cytoskeleton organization is circular in uPAR
-/- ECs: Lack of uPAR expression induces changes in cell morphology and actin
cytoskeleton. Quiescent WT (A, C) and uPAR
-/- (B, D) ECs were plated on Vn and allowed to adhere for 4 hr and then stained for actin with
phalloidin-FITC. Cells stained for actin (green) and the nucleus (blue) were imaged using a confocal microscope. Images obtained using a 30×
objective (A, B) revealed morphological differences between WT and uPAR
-/- ECs. Images at higher magnification (100× objective) (C, D)
demonstrated that while the WT cells showed polarized actin formation, the uPAR
-/- ECs maintained an atypical concentric actin organization.
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observed in WT cells. Endogenous FAK(P-Tyr925) has
been implicated in focal adhesion disassembly resulting
in normal focal adhesion turnover and hence a migra-
tory phenotype for the cell. On the other hand hyper-
phosphorylation of FAK(P-Tyr925) in uPAR
-/- EC
resulted in increased cytoplasmic localization of FAK,
but not total exclusion of FAK from focal adhesions.
This suggests that the levels of FAK(P-Tyr925) in focal
adhesions are still sufficient to promote adhesion of
the cells to Vn.
Paxillin is another major component of the focal adhe-
sion complex playing a pivotal role in cell attachment
and motility. This adaptor protein is phosphorylated at
different sites. Phosphorylation at Tyr118 is catalyzed by
FAK [43] and this step is important for coordinating
formation of focal adhesions and associated actin
network [44]. Immunofluorescence staining was per-
formed on WT and uPAR
-/- ECs after 4 hr adhesion on
Vn to determine the localization and distribution of Pax
(P-Tyr118). In WT cells, Pax(P-Tyr118) was present as
plaques in the lamellipodia protrusions, whereas in the
uPAR
-/- ECs there is complete lack of lammellipodia
and the Pax(P-Tyr118) was observed as focal adhesions
around the cell periphery and central region (Figure 5C,
D). Localization of Pax(P-Tyr118) at focal adhesions,
and actin organization, are inter-dependent processes
[44,45], and tethered to the actin filaments [46]. There-
fore, changes to the actin organization can affect the
localization of paxillin. Since in uPAR
-/- ECs actin orga-
nization is circular, corresponding peripheral and central
circular localizations of Pax(P-Tyr118) were observed in
these cells (Figure 5D). In adherent WT cells that
showed polarized actin organization and robust
Figure 5 uPAR
-/- ECs demonstrated changes in focal adhesion proteins FAK(P-Tyr925), Pax(P-Tyr118), integrins, and signal
transduction:( A) WT cells adherent on Vn for 4 hr were stained for FAK(P-Tyr925) (green) and the nucleus (blue) and were imaged using an
100× objective. FAK(P-Tyr925) was found to be localized on focal adhesions (arrow) in WT cells. (B) uPAR
-/- ECs stained for FAK(P-Tyr925)
demonstrated that FAK(P-Tyr925) was present not only along the cellular membrane (arrow) but also centrally in the cytoplasm (arrow). (C)
Similar to (A), WT cells adherent on Vn were stained for Pax(P-Tyr118) (green) and DNA (blue). Images (100× objective) demonstrated that Pax(P-
Tyr118) is present mainly along the focal adhesions and lamellipodia (arrow) in WT cells. Robust lamellipodia formation was observed. (D) Pax(P-
Tyr118) (green) localization in uPAR
-/- ECs adherent on Vn occurred along the focal adhesions (arrow) of the circularly shaped cell as well as
centrally within the cytoplasm (arrow). Lack of lamelllipodia formation was observed in uPAR
-/- ECs (B, D). (E) Immunoblot analyses of focal
adhesion proteins and STAT1. Quiescent WT and uPAR
-/- ECs were seeded on Vn-coated 6-well plates and allowed to adhere for 4 hr. The
medium was aspirated and the cell lysates were utilized for analyses. Levels of integrins b1, b3, and FAK(P-Tyr925) were determined by IP of 100
μg of cell lysates. Levels of integrin b1 and FAK(P-Tyr925) were enhanced in uPAR
-/- ECs compared to WT cells, while levels of integrin b3, total
FAK, and paxillin were similar between WT and uPAR
-/- ECs. uPAR
-/- ECs showed decreased levels of STAT1 compared to WT cells. Tubulin served
as a loading control. (F) The graph shows the levels of FAK(P-Tyr925/FAK), STAT1/tubulin, and Integrin b1/tubulin between WT and uPAR
-/- ECs.
The values obtained represent the mean ± SEM of three independent assays. Significance levels (*) indicates p value of < 0.05 between WT and
uPAR
-/- cells.
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adhesions were associated with lamellipodia protrusions.
It has been reported that modification of cytoskeletal
proteins affects paxillin expression [45]. However,
changes in the actin network in uPAR
-/- cells had little
effect on the expression of paxillin (Figure 5E). Since
vinculin is another component of focal adhesions and is
associated with paxillin [47], adherent cells were immu-
nostained for vinculin after 4 hr. It was observed that in
both WT and uPAR
-/- ECs plated on Vn, cellular locali-
zation of vinculin was more perinuclear (Additional File
2, Figure S2A,B). Cellular localization of vinculin on
WT and uPAR
-/- ECs plated on collagen was associated
with focal adhesions (Additional File 2, Figure S2C,D).
Thus, it appears that subcellular localization of vinculin
is independent of actin organization or uPAR, but
dependent on the type of ECM on which the cells are
plated.
The Rho family of GTPases, viz., Rac1, cdc42, and
RhoA, play an important role in actin cytoskeleton regu-
lation of lamellipodia and filopodia formation, thus con-
trolling cell adhesion, motility, and growth [48,49]. Rac
activation is dependent on the interaction of uPAR with
Vn followed by protrusive activity and lamellipodia for-
mation [10]. To investigate whether Rac activation is
affected in uPAR
-/- cells adherent on Vn, conditions
where cell morphology was affected, levels of activated
Rac were determined on ECs after 4 hr of adhesion. As
observed in Additional File 3, figure S3A, GTP-loaded
Rac was diminished in uPAR
-/- ECs, but was present in
WT cells. Since functioning of Rac and RhoA is inter-
connected, and RhoA regulates formation of actin bun-
dles and focal adhesions, the spatial arrangement of Rho
was examined in WT and uPAR
-/- cells on Vn and col-
lagen. In WT cells, RhoA is located centrally throughout
the cell when plated on VN and collagen (Additional
File 3, Figure S3B,D). On the other hand, in the uPAR
-/-
ECs, RhoA appears to be present on the membrane
when adhered to collagen, but is perinuclear when pla-
ted on Vn (Additional File 3, Figure S3E,C). The central
localization of Rho in WT cells is consistent with its
function of generating tension and stabilizing adhesions
[50].
ECs interact with Vn via members of the integrin
family of ECM receptors, which in-turn are known to
mediate tyrosine phosphorylation of FAK, thus regulat-
ing cell adhesion and migration [51]. In particular, it is
k n o w nt h a tE C sp r e d o m i n a n t l yb i n dt oV nv i at h ea5b1
and aVb3 integrins [52], and that uPAR is known to
associate with b1a n db3 integrins [53]. Given our
observation that uPAR
-/- ECs demonstrate perturbations
in adhesive properties, key components of the cytoskele-
tal components, and focal adhesions, expression levels
of b1a n db3 integrins in cells adherent to Vn for 4 hr
were evaluated. It was observed that b1 integrin levels
were elevated in uPAR
-/- ECs (Figure 5E,F), whereas
expression of b3 integrins was similar to WT cells (Fig-
ure 5E). These results suggest that absence of uPAR
increased expression of b1 integrin leading to higher
levels of Vn cell surface receptors and elevated adhesion
of uPAR
-/- cells to Vn. It has been shown that STAT1
plays an important role in cell adhesion in different cell
types and that STAT1
-/- embryonic fibroblasts demon-
strated higher levels of adhesiveness and decreased
migration on fibronectin compared to WT cells [54,55].
Therefore, STAT1 levels were evaluated in WT and
uPAR
-/- ECs after 4 hr of adhesion on Vn. STAT1 levels
in uPAR
-/- ECs were lower compared to WT cells (Fig-
ure 5E,F).
Sprout formation and capillary morphogenesis is
impaired in uPAR
-/- ECs
We show that uPAR
-/- cells are altered in their angio-
genic properties, e.g., proliferation, migration, and adhe-
sion compared to WT cells when plated on Vn. To
determine whether these altered angiogenic functions
translate into an inability of the uPAR
-/- ECs to form
capillary sprouts and lumen, a microcarrier-based fibrin
gel angiogenesis assay was performed in vitro. WT and
uPAR
-/- ECs adherent to collagen-coated cytodex beads
were embedded in a fibrin matrix [56,57], which is
known to induce EC tube formation in the presence or
absence of VEGF. Capillary morphogenesis was observed
after 24 and 96 hr incubation and stained for actin and
nuclei. After 24 hr, sprouting or elongation of WT and
uPAR
-/- ECs was observed in the absence (Figure 6A,B)
or presence of VEGF (Figure 6C,D). However, the num-
ber of uPAR
-/- cells adhering to the microcarrier bead
was higher (Figure 7A) and in consonance with our
observation that these cells adhere more on collagen
compared to WT cells (Figure 1B). Assessment of
sprout number and length of sprouts per bead revealed
that, in the absence of VEGF, uPAR
-/- ECs developed
more sprouts and the sprout length was longer com-
pared to WT cells (Figure 7B,C). At higher magnifica-
tion it was observed that WT ECs developed robust
filopodia or finger-like projections at the end of the
sprout after 24 hr, but the uPAR
-/- ECs developed
sprouts that were thinner with poorly developed filopo-
dia structures (Figure 6, boxed areas). The presence of
VEGF (10 ng/ml) did not appear to significantly
enhance the number of cells adherent to the beads or
the number and length of sprouts of WT cells (Figure
7A,B,C). However, sprout length of uPAR
-/- ECs was
increased in the presence of VEGF (Figure 7C).
After 96 hr it was observed that WT ECs were able to
organize into lumen-containing capillary-like structures
(Figure 8A,C). However, uPAR
-/- cells were unable to
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scarce and irregular in shape (Figure 8B,D). The uPAR
-/-
ECs appeared to grow longer sprouts that are highly
branched and that could contact another vessel, but
were unable to undergo normal anastomosis and form
lumen-like structures, as was the case with WT cells.
Thus, it is concluded that depletion of uPAR in angio-
genically functional ECs disrupts cell migration, prolif-
eration, adhesion, and anastomosis, events that are
crucial for new blood vessel growth in vivo.
uPAR
-/- mice demonstrate impaired neovascularization in
vivo
In order to further demonstrate that uPAR is required
for promoting normal angiogenesis, an experimental
model of in vivo blood vessel formation was performed.
Matrigel matrix containing VEGF (10 ng/ml) was
injected subcutaneously in WT and uPAR
-/- mice and
incubated for 14 days. The Matrigel plug was excised
and stained for a-smooth muscle actin to detect forma-
tion of new blood vessels in the Matrigel implants.
Immunofluorescence imaging revealed that implants
from WT mice showed the presence of robustly formed
capillaries, whereas implants from uPAR
-/- mice con-
tained several tiny punctate capillary-like vessels (Figure
9A,B). These results indicate that the absence of uPAR
did not support normal vessel formation within the
Matrigel plug which was further supported by in vitro
observations demonstrating altered proliferation and
migratory properties which would contribute to an
inability of these cells to organize into functional blood
vessels.
Discussion
The uPAR protein is a versatile molecule that coordi-
nates a number of cellular processes [9,58]. These
include its interaction with Vn [8], which is required for
maintaining normal physiological activities, such as
Figure 6 In vitro angiogenesis is impaired in uPAR
-/- ECs:( A) WT cells on cytodex beads and embedded in a fibrin matrix were stained for
actin using phalloidin-TRITC (red) and DNA (blue) and imaged using a 100× objective. After 24 hr incubation the bead was surrounded by
adherent cells which were elongated. (B) Enhanced elongation of sprouts was observed from uPAR
-/- ECs adherent on the beads and these
sprouts appeared to be thinner. (C) Sprout elongation by WT cells in the presence of 10 ng/ml of VEGF. Boxed area shows the development of
robust lamellipodia formation of WT cells. (D) Elongation process after 24 hr for uPAR
-/- ECs in the presence of 10 ng/ml of VEGF. Boxed area
shows that the sprouts derived from the uPAR
-/- ECs are thinner and show truncated lamellipodia formation.
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levels are known to increase during pathological condi-
tions of rheumatoid arthritis [61] and tumor invasion
[62]. The role of uPAR in pathological angiogenesis is
well established and down-regulating uPAR expression
in cancerous cells attenuates tumor growth, accompa-
nied by decreased cellular migration, invasion, and adhe-
sion [63-65]. In this study, uPAR
-/- ECs demonstrated
enhanced adhesion compared to WT cells when tested
on Vn and collagen, but not on fibronectin. It is known
that uPAR is required for cells to adhere to Vn and col-
lagen [27,28], which then regulates integrin-mediated
signaling [66]. In the absence of uPAR the ECs show a
“fried egg” morphology and lack lamellipodia formation
when plated on Vn compared to WT cells. However
these cells exhibited normal cell morphology on col-
lagen. Thus, further evaluations of different focal
adhesion and signaling molecules were performed on
ECs adherent on Vn. It was also observed that levels of
b1-integrins in uPAR
-/- ECs were increased after adhe-
sion on Vn with a concomitant increase in focal adhe-
sion protein FAK(P-Tyr925). Thus in the absence of
uPAR, which would otherwise bind to Vn, the presence
of enhanced levels of b1-integrin and FAK(P-Tyr925) in
uPAR
-/- ECs is most likely responsible for enhanced
adhesion of these cells to Vn. Indeed, it has been
reported that HEK293 cells not expressing uPAR are
capable of integrin-mediated adhesion to Vn but fail to
do so under integrin blocking conditions [21]. Aberrant
integrin and FAK signaling is known to facilitate tumor
cell invasion and metastasis. However, its activation in
each cell type is interpreted differently and current
knowledge regarding integrin/FAK signaling is contra-
dictory and dependent on interactions with other focal
Figure 7 Quantification of in vitro tube formation assay:( A) Quantification of the number of cells adherent on the beads. Increased number
of uPAR
-/- ECs adhered to the beads compared to WT cells, both in the absence or presence of VEGF. (B) Increased number of sprouts/bead was
observed in uPAR
-/- cells in the absence or presence of VEGF compared to WT cells. (C) uPAR
-/- cells demonstrated increased sprout length
compared to WT ECs in the absence and presence of VEGF. Ten beads/treatment/experiment/genotype were analyzed and the graph represents
the mean ± SEM of three independent assays. (*) Denotes significance between control WT and uPAR
-/- ECs and (**) identifies significance
between WT and uPAR
-/- ECs in the presence of VEGF. p value were < 0.05 between WT and uPAR
-/- cells.
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Shc [67,68]. As shown schematically in Figure 10, inter-
action of uPA with uPAR results in generation of plas-
min that degrades the extracellular matrix facilitating
cellular migration and proliferation. Even though the
uPAR
-/- ECs exhibited increased adhesion on Vn and
collagen, a total uPAR deficiency would lead to compro-
mised uPA/uPAR interaction, thus preventing uPA/
uPAR-dependent proteolysis that would otherwise posi-
tively influence cellular migration and proliferation.
Figure 8 Tubulogenesis is impaired in uPAR
-/- ECs: Bead-based fibrin gel angiogenesis was observed at 96 hr and the cells were stained for
actin using phalloidin-TRITC (red) and DNA (blue) and imaged using a 20× objective. Formation of capillary-like structures at 96 hr in WT cells in
control (A) assay and in the presence of 10 ng/ml VEGF was observed (C). In beads plated with uPAR
-/- ECs, highly branched sprouts were
observed but were not organized to form capillary-like structures in the absence or presence of VEGF (B, D).
Figure 9 Effect of a uPAR deficiency on angiogenesis in an in vivo Matrigel assay: Matrigel containing 10 ng/ml VEGF was implanted s.c.
and recovered on day 14 after implantation, fixed, and stained for smooth muscle a-actin to observe capillary formation. (A) Representative
image of Matrigel implant excised from WT mouse shows the presence of robust and well-developed capillaries (arrows). (B) Representative
image of Matrigel implant excised from uPAR
-/- mouse shows the presence of several truncated structures that have not been organized to form
a functional capillary (arrows).
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observed when uPAR
-/- ECs were plated on Vn, and the
associated increased levels of other proteins, such as
FAK(P-Tyr925) and Paxillin, could be responsible for
the uPAR
-/- EC phenotypes on Vn. Mechanistically, the
interaction of uPAR with Vn leads to Rac activation,
which in turn affects actin organization and formation
of protrusions in an uPA-independent manner in Swiss
3T3 cells [10]. The uPAR
-/- E C sa d h e r e n to nV nl a c k e d
GTP-loaded Rac. RhoA localization in these cells was
mostly present at the peripheral edge when cells
adhered to collagen and perinuclear when adhered to
Vn. This suggests that in order to have normal asso-
ciated cytoskeletal structures and actin organization
when bound to Vn the cells must express uPAR. How-
ever, the perinuclear localization of vinculin in WT and
uPAR
-/- ECs, which is another important component of
the focal adhesion complex and is known to complex
with FAK and paxillin, was dependent on Vn. Vinculin
at focal adhesions was observed only when WT and
uPAR
-/- ECs were plated on collagen and hence its loca-
lization is uPAR-independent.
uPAR
-/- ECs expressed decreased levels of STAT1
relative to WT cells. It has been reported that absence
of STAT1 signaling is accompanied by increased cell
adhesion on fibronectin, but poor migration [69], an
observation that was similar to that observed in uPAR
-/-
ECs. Since cell adhesion and cytoskeleton morphology is
intrinsically linked with migration, the decreased migra-
tion of uPAR
-/- ECs on Vn is probably associated with
the perturbed cytoskeletal organization and engagement
of focal adhesion proteins of these cells to the matrix.
Gondi et al., (2004) [70] have shown that RNAi-
mediated down regulation of uPAR expression in
Figure 10 A simplified schematic depiction of the role of uPAR in angiogenesis: The uPAR/Pro-uPA interaction leads to the generation of
active uPA on the cell surface. This complex binds to vitronectin in the extracellular matrix, allowing interaction with its transmembrane
partners, the a/b integrins. This leads to a cascade of activation events resulting in tyrosine phosphorylation of focal adhesion kinase (FAK) and
paxillin molecules. Through recruitment of other adaptor molecules, such as Src and p130Cas-CRK complex (not shown), Rac is activated.
Activated Rac then induces actin filament assembly leading to membrane protrusion and motility. Formation of focal adhesion complexes
enables cellular adhesion and migration. The uPA/uPAR complex also generates the serine protease, plasmin that degrades the extracellular
matrix (ECM) thereby stimulating conditions for migration and proliferation. The transmembrane partnership between uPA/uPAR and a/b
integrins also activates mitogen activated kinase signaling molecules, MEK and ERK1/2, as well as the phosphoinositide 3-kinase (PI3K)/Akt
signaling axis. Thus uPAR-dependent multiple signaling events regulates cellular adhesion, proliferation, and migration, events associated with
angiogenesis.
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migration, proliferation, and invasion, but had no effect
on phosphorylation of ERK1/2 and FAK. Our observa-
tions regarding P-ERK1/2 are consistent with those
observed in the uPAR down-regulated SNB19 cells, but
in uPAR
-/- ECs FAK phosphorylation was increased.
This could be due to differences in cell types such as
the ECs utilized in this study. Similarly, knockdown of
uPAR expression in PC3 prostrate cancer cell lines also
diminished cell proliferation and inhibited Matrigel
invasion of PC3 cells without affecting ERK1/2 activa-
tion [17].
uPAR
-/- ECs also exhibited diminished capacity to
undergo tubulogenesis both in vitro and in vivo. The
inability of the uPAR
-/- ECs to form lumen-like struc-
tures in a fibrin matrix could not be related to differ-
ences in VEGF receptor signaling between WT and
uPAR
-/- ECs, as the VEGF receptor-1 (Flt-1) levels and
its phosphorylated form were similar in the two geno-
types (data not shown). Previous studies have demon-
s t r a t e dt h a tt h e s eE C sd on o te x p r e s sV E G F R - 2[ 2 4 ] .I t
was demonstrated in systemic sclerosis microvascular
ECs (SSc MVECs) that full length uPAR is required for
cdc42- and Rac-mediated cytoskeletal organization. SSc
MVECs express a truncated form of uPAR that lacks
the D1 domain and are incapable of forming tubular-
like structures. Instead, elongated cells with very little
evidence of capillary-like structures were observed [71].
Similarly, Matrigel implants excised from uPAR
-/- mice
and stained for a-smooth muscle actin revealed a lack
of robustly formed blood vessels. For several years it
was thought that the uPAR
-/- mice do not have physio-
logical abnormalities as they appeared normal and were
fertile. However, several recent investigations have docu-
mented that uPAR
-/- mice are deficient in several phy-
siological functions. Bone homeostasis in uPAR
-/- mice
is affected due to increased bone mass, increased osteo-
genic potential of osteoblasts, decreased osteoclast for-
mation, and altered cytoskeleton organization in
matured osteoclasts characterized by actin rings and
podosomes clusters when cultured on Vn [72]. Wei et
al., (2008) [73] demonstrated that a concerted signaling
pathway involving uPAR/avb3/Vn is required for devel-
opment of podocyte foot process effacement and protei-
nuria, thus implicating the involvement of uPAR in
remodeling of the kidney barrier function. Additionally,
uPAR is involved in the recruitment and infiltration of
macrophages into the lungs and inflamed peritoneal cav-
ity of mice challenged with Streptococcus pneumoniae
[74,75]. Interestingly, although uPAR
-/- mice survive
through adulthood they exhibit increased anxiety beha-
vior and are susceptible to spontaneous seizure activity
that are thought to be due to decreased levels of GABA-
immunoreactive interneurons in the brain cortex thus
causing changes in circuit organization and behavior
[76]. Thus the uPAR protein is a very versatile molecule
and binding to ECM (mainly Vn) can modulate several
physiological processes in a proteolytic-independent
manner.
Additional material
Additional file 1: A Deficiency of uPAR Alters Endothelial
Angiogenic Function and Cell Morphology. Figure S1.
Immunostaining analysis of microtubulin in WT and uPAR
-/- ECs: Cells
adherent on Vn- and collagen-coated oncyte wells for 4 hr were stained
with a microtubulin specific antibody (red) and DAPI nuclear stain (blue)
and images acquired using a 100× objective. WT (A) and uPAR
-/- (B) ECs
plated on Vn show similar microtubule organization. (C) WT cells plated
on collagen showed similar microtubule organization as observed on Vn.
(D) However, uPAR
-/- cells plated on collagen contain parallel bundles of
microtubules that closely approach the plasma membrane, an
arrangement not observed in WT cells.
Additional file 2: A Deficiency of uPAR Alters Endothelial
Angiogenic Function and Cell Morphology. Figure S2. Perinuclear
localization of vinculin in WT and uPAR
-/- ECs when plated on Vn: WT
and uPAR
-/- cells adherent on Vn-coated and collagen-coated oncyte
wells for 4 hr were stained with vinculin (red), and DAPI nuclear stain
(blue) and images acquired using a 100× objective. It was observed that
when WT (A) and uPAR
-/- (B) ECs are plated on Vn, vinculin is localized
around the nucleus. When WT (C) and uPAR
-/- (D) ECs were plated on
collagen, vinculin was localized on focal adhesion points.
Additional file 3: A Deficiency of uPAR Alters Endothelial
Angiogenic Function and Cell Morphology. Figure S3. Effect of uPAR
deficiency on Rac activity and RhoA localization: (A) Cell lysates (800
μg) from WT and uPAR
-/- ECs adherent on Vn for 4 hr were assayed to
determine Rac activity. PAK-1 PBD agarose bound to Rac-GTP was
fractionated on a 12% SDS-PAGE gel followed by immunoblotting for
Rac. It was observed that uPAR
-/- ECs lack endogenous Rac activity
compared to WT cells even though total Rac levels were similar. (B, C, D,
E) WT and uPAR
-/- cells adherent on collagen- or Vn-coated oncyte wells
for 4 hr were stained with an antibody to RhoA (red), and DAPI nuclear
stain (blue) and images acquired using a 100× objective. It was observed
that in WT cells on Vn (B) RhoA is concentrated in a ‘halo’ around the
nucleus while in uPAR
-/- ECs (C) RhoA is localized along the membrane.
(D) WT cells on collagen demonstrated cytosolic punctate staining of
RhoA. (E) Perinuclear localization of RhoA is observed in uPAR
-/- cells
adherent on collagen.
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